Literature DB >> 3538546

Immunosuppressive activity of serum from liver-grafted rats. Passive enhancement of fully allogeneic heart grafts and induction of systemic tolerance.

N Kamada, T Shinomiya, T Tamaki, K Ishiguro.   

Abstract

Immunological enhancement of allogeneic heart graft survival by serum from rats tolerized by liver grafting has been studied. Serum taken from long-term-surviving PVG rats carrying orthotopic DA liver transplants (OLT serum) was able to increase the survival time of PVG.RT1a heterotopic heart grafts in PVG recipients. Administration of 1 ml of OLT serum at the time of heart grafting led to permanent survival of the grafts in all animals. The recipients became systemically tolerant of RT1a and several weeks later were able to accept permanently skin grafts from the same donor strain, while rejecting third-party grafts. Enhancement appeared to be mediated initially by IgG antibodies in the OLT serum against class II donor RT1a antigens; significant enhancement was produced by as little as 100 micrograms of antibody. Recipient alloantibody responses following enhancement were studied and showed selective suppression of the anti-class-I (RT1Aa) antibody levels, while the anti-class-II antibody response was apparently unaffected. The implications of these results for mechanisms of unresponsiveness following enhancement and liver transplantation are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3538546     DOI: 10.1097/00007890-198612000-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  13 in total

1.  Immunological tolerance induced by liver grafting in the rat: splenic macrophages and T cells mediate distinct phases of immunosuppressive activity.

Authors:  S Yoshimura; S Gotoh; N Kamada
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

2.  Mechanisms in passive enhancement of cardiac and renal allografts by serum from liver-grafted rats.

Authors:  A Yamaguchi; N Kamada
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

Review 3.  [Immunologic tolerance after experimental liver transplantation].

Authors:  M Knoop; U Neumann; P Neuhaus
Journal:  Langenbecks Arch Chir       Date:  1995

4.  FcR blocking activity in serum of actively enhanced rat renal allograft recipients due to IgG anti-class II MHC alloantibody.

Authors:  H E Marshall; E M Bolton; J A Gracie; J E Cocker; G P Sandilands; J A Bradley
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

5.  Mechanisms of transplantation tolerance induced by liver grafting in rats: involvement of serum factors in clonal deletion.

Authors:  N Kamada; R Sumimoto; A Baguerizo; A Yoshimatsu; K Teramoto; A Yamaguchi
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

6.  Liver graft induced donor specific unresponsiveness without class I and/or class II antigen differences.

Authors:  S Qian; H Sun; A J Demetris; F Fu; T E Starzl; J J Fung
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

7.  The role of antibodies in liver graft-induced tolerance in mice: passive transfer of serum and effect of recipient B-cell depletion.

Authors:  U Dahmen; H Sun; Y Li; F Fu; A J Demetris; T E Starzl; S Qian; J J Fung
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

8.  Analysis of T cell responses in liver allograft recipients. Evidence for deletion of donor-specific cytotoxic T cells in the peripheral circulation.

Authors:  J M Mathew; J W Marsh; B Susskind; T Mohanakumar
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

9.  Immunosuppressive activity of serum from liver-grafted rats: in vitro specific inhibition of mixed lymphocyte reactivity by antibodies against class II RT1 alloantigens.

Authors:  M Tsurufuji; K Ishiguro; T Shinomiya; T Uchida; N Kamada
Journal:  Immunology       Date:  1987-08       Impact factor: 7.397

10.  De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.

Authors:  H Kaneku; J G O'Leary; N Banuelos; L W Jennings; B M Susskind; G B Klintmalm; P I Terasaki
Journal:  Am J Transplant       Date:  2013-06       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.